Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity

9 novembre 2026 aggiornato da: Dr. August Wolff GmbH & Co. KG Arzneimittel

Double-blind, Randomized, Non-inferiority Clinical Study to Evaluate the Efficacy of a Toothpaste Containing 20% Hydroxyapatite (HAP) and 2% Calcium Hypophosphite (CaP) Compared With Two Comparator Toothpastes by Assessing the Impact on Symptoms of Dentin Hypersensitivity Over a Study Duration of 56 Days (8 Weeks), as Well as Its Safety and Tolerability in Research Participants With Dentin Hypersensitivity

This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes.

A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days.

The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups.

Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.

Panoramica dello studio

Descrizione dettagliata

Only the main outcome measures and the main inclusion and exclusion criteria are listed in this record. Further secondary and exploratory endpoints as well as the complete eligibility criteria are specified in the study protocol.

Tipo di studio

Interventistico

Iscrizione (Stimato)

186

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Valinhos
      • São Paulo, Valinhos, Brasile, 13270-180
        • Reclutamento
        • Kosmoscience

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Men and women aged between 18 and 65 years.
  • Presenting with dentin hypersensitivity.
  • At least one eligible tooth (incisor, canine, premolar, or first molar) must have visibly exposed cervical dentin on the facial surface and a score at least 30 mm on the 100-mm VAS immediately after the airblast test (VAS: 0 mm: no sensitivity; 100 mm: worst imaginable sensitivity)
  • Proper periodontal health (i.e. no probing depth > 4 mm, or other conditions that might explain their apparent dentin hypersensitivity
  • To be in good general health, as assessed by the investigator.

Exclusion Criteria:

  • Previous professional desensitizing treatment within the past 3 months (e.g., in-office fluoride varnish, laser desensitization)
  • Use of over-the-counter desensitizing products within the previous 8 weeks
  • Medical histories made remarkable by chronic use of antibiotics, anti-inflammatory, analgesic, anticonvulsant, sedative, and psychotropic drugs; or ongoing active treatment with any of these drug classes at the time of screening
  • Pregnancy and breastfeeding
  • Allergies and idiosyncratic responses to product ingredients (e.g., any ingredient of the investigational or comparator products)
  • Teeth or periodontium with pathology or defects likely to cause pain (e.g., periodontal abscess, tooth mobility greater than Grade 1) (applies to teeth designated for sensitivity assessment)

Only the main eligibility criteria are listed. The complete criteria are specified in the study protocol.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 20% Hydroxyapatite and 2% Calcium Hypophosphite Toothpaste

Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

Comparatore attivo: Stannous Fluoride Toothpaste

Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

Comparatore attivo: 8% Arginine Toothpaste

Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56
Lasso di tempo: Baseline (Day 1) to Day 56 (±3 Days)

The primary endpoint is the mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56 between the test group and both control groups. VAS: 0 mm: No sensitivity; 100 mm: worst imaginable sensitivity. Non-inferiority will be assessed separately for the investigational toothpaste versus each of the two comparator toothpastes, using a predefined non-inferiority margin (δ) of 10 mm on the VAS scale (0-100 mm).

Baseline (Day 1) to Day 56 (±3 Days)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean change in VAS (Cold Water Test) from Baseline to Day 56
Lasso di tempo: Baseline (Day 1) to Day 56 (±3 Days)

Mean change in VAS (Cold Water Test) from Baseline to Day 56 between the test group and each of the two control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Baseline (Day 1) to Day 56 (±3 Days)
Mean change in VAS (Airblast test) from Baseline to Day 28
Lasso di tempo: Baseline (Day 1) to Day 28 (±3 Days)

Mean change in VAS (Airblast test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Baseline (Day 1) to Day 28 (±3 Days)
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application
Lasso di tempo: Day 1 (Baseline and directly after the first application)

Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Day 1 (Baseline and directly after the first application)
Mean change in VAS (Cold Water test) from Baseline to Day 28
Lasso di tempo: Baseline (Day 1) to Day 28 (±3 Days)

Mean change in VAS (Cold Water Test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Baseline (Day 1) to Day 28 (±3 Days)
Mean change in VAS (Cold Water test) from Baseline to Day 1 directly after the first application
Lasso di tempo: Day 1 (Baseline and directly after the first application)

Mean change in VAS (Cold Water Test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Day 1 (Baseline and directly after the first application)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ana Lúcia Tabarini Alves Pinheiro, MD, Kosmoscience Ciência e Tecnologia Cosmética, Importação e Exportação Ltda.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 novembre 2026

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 febbraio 2027

Date di iscrizione allo studio

Primo inviato

9 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

All data and information retrieved within the investigation are an intellectual property of the Sponsor.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi